Serosurveillance of dengue infection and correlation with aedine mosquito pools for dengue virus positivity during the COVID-19 pandemic in Tamil Nadu, India – A state-wide cross-sectional cluster randomized community-based study

Sivaprakasam T. Selvavinayagam[1¶], Sathish Sankar[2¶], Yean K. Yong[3¶], Abdul R. Anshad[4], Samudi Chandramathi[5], Anavarathan Somasundaram[6], Sampath Palani[1], Parthipan Kumarasamy[1], Roshini Azhaguvel[1], Ajith B. Kumar[1], Sudharshini Subramaniam[6], Manickam Malathi[7], Venkatachalam Vijayalakshmi[7], Manivannan Rajeshkumar[1], Anandhazhvar Kumaresan[1], Ramendra P. Pandey[8], Nagarajan Muruganandam[9], Natarajan Gopalan[10], Meganathan Kannan[11], Amudhan Murugesan[12], Pachamuthu Balakrishnan[13], Siddappa N. Byrareddy[14], Aditya P. Dash[15], Marie Larsson[16], Vijayakumar Velu[17], Esaki M. Shankar[4*] and Sivadoss Raju[1*]

[1]State Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai, Tamil Nadu, India
[2]Centre for Infectious Diseases, Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
[3]Laboratory Centre, Xiamen University Malaysia, Sepang, Selangor, Malaysia
[4]Infection and Inflammation, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur, India
[5]Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Lembah Pantai, Kuala Lumpur, Malaysia
[6]Institute of Community Medicine, Madras Medical College, Chennai, Tamil Nadu, India
[7]Institute of Vector Control and Zoonoses, Hosur, Tamil Nadu
[8]School of Health Sciences and Technology, UPES, Dehradun, Uttarakhand, India
[9]Regional Medical Research Centre, Indian Council of Medical Research, Port Blair, Andaman and Nicobar Islands, India
[10]Department of Epidemiology and Public Health, Central University of Tamil Nadu, Thiruvarur, India
[11]Blood and Vascular Biology, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur, India
[12]Department of Microbiology, Government Theni Medical College and Hospital, Theni, Tamil Nadu, India
[13]Center for Infectious Diseases, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
[14]Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
[15]Asian Institute of Public Health University, Bhubaneswar, Odisha, India
[16]Division of Molecular Medicine and Virology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
[17]Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Division of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA.

¶These authors contributed equally to this work

***Corresponding authors**

sivraju@gmail.com (SR)

shankarem@cutn.ac.in (EMS)

Running title: Dengue seroprevalence in COVID-19 pandemic

Data Availability Statement

The data that support the findings of this study including deidentified participant data and specific datasets will be available from the corresponding author upon reasonable request by email. The data will be available beginning five months and ending three years after publication. Data requestors will be required to sign a data access agreement before data are released.Data requests can be sent to the corresponding author through email.

Funding

The study was funded by the National Health Mission, Tamil Nadu (680/NGS/NHMTNMSC/ENGG/2021) for the Directorate of Public Health and Preventive Medicine to S.T.S. and S.R. are funded. M.L. is supported by grants through AI52731, the Swedish Research Council, the Swedish, Physicians against AIDS Research Foundation, the Swedish International Development Cooperation Agency, SIDASARC, VINNMER for Vinnova, Linköping University Hospital Research Fund, CALF, and the Swedish Society of Medicine. V.V. is supported by the Office of Research Infrastructure Programs (ORIP/NIH) base grant P51 OD011132 to ENPRC. A.M. is supported by Grant No. 12020/04/2018□HR, Department of Health Research, Government of India.

Competing interests

There are no conflicts of interest to disclose by any authors.

Ethics statement

The study was approved by the Institutional Ethical Committee of Madras Medical College and Hospital, Chennai (EC No. 03092021). Written informed consent was obtained from the study participants.

Abstract

Background

Dengue is a vector-borne viral disease impacting millions across the globe. Nevertheless, akin to many other diseases, reports indicated a decline in dengue incidence and seroprevalence during the COVID-19 pandemic (2020-22). This presumably could be attributed to reduced treatment-seeking rates, under-reporting, misdiagnosis, disrupted health services and reduced exposure to vectors due to lockdowns. Scientific evidence on dengue virus (DENV) disease during the COVID-19 pandemic is limited globally. A community-based, cross-sectional, cluster-randomized survey was carried out to assess dengue and SARS-CoV-2 seroprevalence in humans and DENV-positivity in aedine mosquito vectors in Tamil Nadu, India during the SARS-CoV-2 pandemic.

Methods and Findings

A cross-sectional, randomized cluster sampling community-based survey was carried out to assess anti-dengue IgM and IgG and SARS-CoV-2 IgG seroprevalence across all 38 districts of Tamil Nadu, India. The prevalence of DENV in the Aedes mosquito pools during 2021 was analyzed and compared with previous and following years of vector surveillance for DENV by real-time PCR.

Results implicate that both DENV-IgM and IgG seroprevalence and mosquito viral positivity were reduced across all the districts. A total of 13464 mosquito pools and 5577 human serum samples from 186 clusters were collected. Of these, 3.76% of mosquito pools were positive for DENV. In the human sera, 4.12% were positive for DENV IgM and 6.4% were positive for DENV IgG. The anti-SARS-CoV-2 antibody titres correlated with dengue seropositivity with a significant association whereas vaccination status significantly correlated with dengue IgM levels. Factors associated with the anti-DENV IgM and IgG seropositivity were assessed using a binary regression model. The factors associated with the level of anti-DENV IgM and IgG were assessed using a linear regression model. The major limitation of the study is that viral interference with anti-DENV antibodies and anti-SARS-CoV-2 antibodies was not studied in cell culture models or animal experimentation models.

Conclusions

Continuous monitoring of DENV seroprevalence, especially with the evolving variants of the SARS-CoV-2 virus and the surge in COVID-19 cases will shed light on the transmission and therapeutic attributes of dengue infection.

Key words: COVID-19; Dengue; Serosurveillance; Vector-borne disease

Introduction

Dengue represents a global arboviral public health threat and is caused by four serotypes of dengue virus (DENV1-4). *Aedes* mosquitoes (*Ae. aegypti* and *Ae. albopictus*), act as vectors that dwell in the tropical and subtropical world making the disease hyperendemic across Asia and South America, Africa, the Middle East[1,2] and other temperate parts of the world[3]. The single-stranded positive-sense RNA-laden Flavivirus causes frequent concurrent epidemics involving different serotypes. While DENV2 appears to be associated with severe disease, there is evidence of the distribution of all DENV serotypes in Asia[4]. Dengue is classified as primary and secondary based on IgM:IgG ratio, and two types, viz. dengue without warning signs (DWWS) and dengue with warning signs (DWS) based on clinical manifestations[5,6]. The prognosis of dengue is determined by antibody-dependent enhancement (ADE), viral dynamics, and pre-existing antibody titers[7]. However, protean clinical manifestations, serotype heterogeneity, and co-infections pose a substantial challenge to patient management.

There is a growing interest in prevailing infections post-SARS-CoV-2 pandemic. As with other infections, there has been a shift in the trend of dengue in 2020-22, when COVID-19 was taking a toll. Several studies reported a 16-97% decrease in dengue cases during the pandemic[8–10]. There have been reports of concomitant dengue disease together with other infectious agents, including SARS-CoV-2[11–13]. The pressure that prevailed during the COVID-19 pandemic raised concerns over the lack of attention to dengue diagnosis, reduced treatment-seeking rates, potential for misdiagnosis, reduced availability of laboratory testing for dengue, and negative impact of lockdowns[10]. There has been a declining trend in dengue post-COVID-19 following an upsurge in 2019[14], likely due to the global imposition of lockdowns[15]. In India, dengue incidence was reported to be ~188,000 (2017), 101,192 (2018) and 157,315 (2019) cases. However, the frequency of dengue declined abruptly to 45,585 (71%) (https://ncvbdc.mohfw.gov.in)[16].

Studies reporting dengue decline during the pandemic were often based on serological investigations (NS1/IgM/IgG). Our state-wide entomological surveillance and vector control data indicated a significant reduction of DENV-positive mosquito pools in 2020 that remained low until 2023. This further substantiated our assumption of reduced DENV transmission due to lockdowns. We hypothesized that there is a correlation trend between the SARS-CoV-2 IgG as well as anti-DENV IgM and IgG titers. Possibly, antibodies to SARS-CoV-2 could hinder the circulation of DENV either by protective cross-reaction, antigenic similarity or by masked effects of ADE[17]. The cross-reactive nature of anti-SARS-CoV-2 was reported against various antigens and vaccines[18]. Antibodies to spike and receptor-binding domain (S1-RBD) have been shown to cross-react with both DENV envelope protein (E) and non-structural protein 1 (NS1) in experimental animals[19].

Constant monitoring of disease prevalence and entomological surveillance together with risk factors of viral transmission are critical for highly endemic countries like India. Here, we conducted a community-based, cross-sectional, cluster-randomized survey to assess the seroprevalence of dengue and SARS-CoV-2 and DENV positivity in aedine mosquito vectors in

Tamil Nadu, India in December 2021. The primary and secondary DENV infections along with the antibody titres were correlated with the SARS-CoV-2 IgG in the population.

Methods

Mosquito Sampling

The eggs, larvae, and adult Aedes mosquitoes were collected from all 38 districts of Tamil Nadu indoors and outdoors. The sampling and testing have been carried out as part of the routine surveillance program since 2016 for the prevention and control of vector-borne diseases by the Department of Public Health, Tamil Nadu, India. Here, we compared and analyzed the samples collected from 2016 to mid-2024 for possible correlation with the seroprevalence of SARS-CoV-2 and DENV. The adult female Aedes mosquitoes captured were identified and isolated using a standard method[8] and were transported to the processing laboratory. The eggs hatched after an incubation period of 15 days at the Regional Entomology Laboratory. The larvae and adults were identified and the dried adult mosquito samples were transported in zip-lock covers or microcentrifuge tubes to the State Public Health Laboratory (SPHL), Chennai, and the Institute of Vector Control and Zoonosis (IVCZ), Hosur, India.

Sample Processing

Engorged adult female mosquito pools (n=25) collected from specific trap areas were prepared. The dried adult mosquito pools were crushed and homogenized with 200 µl of Leibovitz's media (L-15) twice with a Teflon pestle homogenizer before centrifuging at 1000 rpm, 4°C for 10 minutes. The supernatant was aliquoted in tubes and stored at –80°C until further use.

RNA Extraction and DENV Detection

The viral RNA from the homogenized mosquito supernatant was extracted using HiPurA pre-filled medium plates-T kit (HiMedia, Maharashtra, India) using a KingFisher Flex automated extraction system (Thermo Fisher Scientific, Waltham, USA). The mosquito pools were screened for DENV using a DENV real-time reverse transcriptase PCR kit (Helini Biomolecules, Chennai, India) in the Quant Studio 5 Real-time PCR System (Applied Biosystems, Waltham, USA) according to the manufacturer's instructions. The kit contained pan-DENV-specific primers and probes for the quantification of DENV1-4 in the FAM channel. The target sequence 5'UTR is highly conserved across all DENV serotypes. The linear range of the assay kit ranged from 1 to $1x10^9$ copies/µl. Possible PCR inhibition and RNA purification efficiency were controlled using an internal amplification control in the HEX channel. In the RT-PCR assay, the cycle threshold (Ct) cut-off value range for DENV positivity was between 13 and 35. Any Ct value >35 was considered DENV-negative while a value <13 was diluted and the assay was repeated.

Study Design and Participants

A community-based, cross-sectional, randomized cluster sampling was carried out to assess the seroprevalence of dengue in all 38 districts of Tamil Nadu, India. The study was approved by the Directorate of Public Health and Preventive Medicine, Government of Tamil Nadu and the Institutional Ethical Committee of the Madras Medical College (Approval No.:03092021). All

individuals were aged >10 years and accented/consented to participate in the investigation. The individuals also included those with suspected or confirmed past dengue infection. From the 38 states, a total of 186 clusters were selected using stratified random sampling.

The size of the cluster was determined based on the population-to-size ratio and was considered an adequate representation of the state. After identifying the cluster, the houses within the cluster were marked and numbered. During the study, a random household was selected and considered as the first household for the study and at least 30 to the left of the primary house were included in the study. The survey team collected all the identification details of the members including socio-demographic details from the selected household. From each household, one respondent was randomly identified for survey sampling using the Kish grid method. Participants were also given a unique ID for identification. At the time of sampling, the participants were enquired about dengue and COVID-19 status, vaccination status, and the type of SARS-CoV-2 vaccine administered.

Clinical Specimens

Considering a 76.9% dengue seroprevalence, a design effect of two, a confidence level of 95% and a precision value of 1.3, the required sample size was calculated as 20. Assuming one-third of the randomly assigned sample would become ineligible due to hemolysis during transportation and refusal to participate in the study, the final sample size was established as 30 per cluster. Two millilitres of venous blood were collected for serum separation before transporting to the District Public Health Laboratory for dengue IgM and IgG ELISA. The other aliquot was transported to the State Public Health Laboratory for SARS-CoV-2 IgG assay.

Anti-DENV IgM and IgG

The extracted serum was tested for IgM as well as IgG antibodies using Panbio Dengue IgM capture ELISA (Abbot Diagnostics, South Korea). Cut-off values were determined as per the manufacturers' instructions. Panbio Units (PU) were calculated as 10 times the value of sample absorbance divided by the cut-off value. A PU value of >11 and <9 was considered positive and negative, respectively. Any value between 9 and 11 was considered equivocal and was tested with the same assay and considered negative if the repeat test value was between 9 and 11. For anti-DENV IgG, a PU value of >22 and <18 were taken as positive and negative, respectively. Any value between 18 and 22 was considered equivocal and was tested with the same assay and considered negative if the repeat test value was between 18 and 22.

Anti-SARS-CoV-2 IgG

The serum samples were tested for SARS-CoV-2 IgG using a commercial anti-SARS-CoV-2 spike-specific quantitative IgG (VITROS S-IgG) assay (Ortho VITROS Immunodiagnostics, New Jersy, USA) as per manufacturers' instructions. The assay kit detects anti-SARS-CoV-2 antibodies, and is FDA-approved under Emergency Use Authorization. The measuring range (or linearity) of the kit was 2-200 BAU/ml. However, based on the limit of quantitation, values ≥17.8 BAU/ml were considered reactive, and otherwise non-reactive.

Statistical Analysis

DENV seroprevalence was estimated using the IgM and IgG levels and corrected using a pre-assessed sensitivity and specificity of the same tests. The corrected prevalence was calculated using the formula: (apparent prevalence + specificity - 1)/(sensitivity + specificity - 1). Force of infection (FOI) was calculated for estimating the seroprevalence in each district, using the WHO-FOI calculator, which assumes a constant FOI over time. The relationship between total population, population density, and mosquito clusters positive for DENV and DENV seropositivity in clinical samples was evaluated using binary logistic regression. The factors associated with DENV seropositivity as well as anti-DENV IgM/IgG levels were evaluated using binary and linear logistic regressions, respectively. Statistical analyses were performed using PRISM, ver.5.02 (GraphPad, San Diego, CA). Binary and linear regression was performed using SPSS, ver.20 (IBM, Armonk, NY), Two-tailed $P<0.05$ was considered significant, and $P<0.05$, <0.01, <0.001, were marked as *, ** and ***, respectively.

Results

DENV Vector Surveillance during 2017-24

To analyze the distribution of DENV-positive mosquitoes, the year-wise surveillance data of the State Public Health Laboratory, Chennai, and the Institute of Vector Control and Zoonoses, Hosur, Department of Public Health, Tamil Nadu between January 2016 and April 2024 were used for the comparison. The highest number of DENV-positive mosquito pools were observed during 2019, with 1440 of 3383 mosquito pools (42.6%). Though there was a two- to five-fold increase in the number of mosquito pools tested in subsequent years, there was a sudden decline during the SARS-CoV-2 pandemic with 8% positivity and a decreasing trend in DENV-positivity until mid-2024. In succeeding years from 2020 until April 2024, the DENV-positivity remained 3-8% (**Figure 1**).

DENV Infestation Rate in Mosquito Pools

Next, we analysed the concurrent seroprevalence of dengue and SARS-CoV-2 in 2021. We noticed a surge in the global COVID-19 burden when mass vaccination programs were rolled out by the Government of India. Of a total of 9764 Aedes mosquito pools tested, 387 (3.96%) tested positive for DENV (**Figure 1**). A decline in the distribution of DENV-infected Aedes mosquitoes was observed during the survey period compared to previous years. Of the 38 districts, Madurai recorded the highest number (n=644) of mosquito pools although the number of DENV-positive mosquito pools was highest in Tenkasi (11.1%) followed by Tirunelveli (8.07%) and Dharmapuri districts (7.89%). All the seven vector pools of the Nilgiris turned negative for DENV (**Fig 1**). The district-wise distribution of DENV in mosquito pools is presented in **S1 Table**.

Figure 1: A) Spatial distribution of DENV-positive mosquito pools in Tamil Nadu, B) Mosquito pools tested DENV positive by year, C) Spatial distribution of seroprevalence of anti-DENV, D) Number of seropositivities for anti-DENV IgM and IgG, E) Distribution of DENV-seropositivity by districts, F-G) Distribution of DENV-seropositivity across different age groups H) Estimation of the force of infection (FOI) of DENV.

Anti-DENV IgM and IgG Seroprevalence in December 2021

Of the 5577 serum samples collected from 186 clusters, 230 samples (4.12%) were positive for anti-DENV IgM whereas 360 (6.4%) were positive for anti-DENV IgG. The highest seroprevalence of anti-DENV IgG was reported in Chennai with 24% while Madurai and Chennai districts recorded the highest (13%) seroprevalence of anti-DENV IgM (**Fig 1**). The age of the recruited population ranged from 10-96 years with a median of 43.6 years (**Table 1**). A high anti-DENV IgM positivity was observed among patients with 30-39 years (n=51; 4.53%), 40-49 years (n=52; 4.59%) and 80-89 years (n=3; 4.84%) of age. Anti-DENV IgG positivity was higher among patients with 10-19 years (n=31; 7.01%), 20-29 years (n=54; 7.16%) and 70-79 years (n=28; 8.95%) of age. All individuals aged between 90 and 99 years (n=7) were negative for both DENV IgM and IgG. The IgM and IgG levels among males were 4.85% and 5.97%, whereas it was 3.57% and 6.81% among females, respectively. Anti-DENV IgM and IgG seroprevalence showed no significant difference among different age groups and between two genders. As the number of participants from the transgender community was low (n=4), no analyses could be performed. The association of patients' domiciliary status (rural and urban) with total DENV seropositivity was highly significant. The seroprevalence of DENV in 38 districts of Tamil Nadu and the FOI in each district are listed in **S2a and S2b Tables**. Overall, the IgG seroprevalence and DENV-positivity in mosquito pools showed low (6.45% and 3.96%, respectively) during the study tenure.

Table 1: Socio-demographic, Clinical and Serological Characteristics of the Study Participants

Total number of participants, *n*	5577
Age, year; *median (IQR)*	43 (31 – 56)
Gender, male; *n (%)*	2329 (41.8%)
SARS-CoV-2 vaccination status, yes; *n (%)*	4654 (83.4%)
AZD1222; *n (%)*	4249 (76.2%)
BBV152, *n (%)*	395 (7.1%)
Others, *n (%)*	10 (0.2%)
History of SARS-CoV-2 infection; *n (%)*	166 (3%)
Hospital admission, *n (%)*	77 (1.4%)
SARS-CoV-2 IgG positivity, *n (%)*	4868 (87.3%)
SARS-CoV-2 IgG titer, *median (IQR)*	200 (80.1 – 200)
History DENV infection; *n (%)*	15 (0.3%)
DENV IgM positivity; *n (%)*	229 (4.1%)
DENV IgG positivity; *n (%)*	356 (6.4%)
DENV IgM titer; *median (IQR)*	2.5 (1.53 – 4.10)
DENV IgG titer; *median (IQR)*	5.10 (2.42 – 9.54)

The association of seroprevalence (IgM/IgG/total) with DENV-positive mosquito pools was investigated using a simple linear regression model with a 95% CI of the slope (**Fig 2A-C**). The association was significantly correlated with IgM and total seropositivity, but not with IgG. The

total DENV positivity was compared with DENV-positive mosquito clusters and DENV-FOI, which revealed no significance, although was evident with DENV-seropositivity (**Fig 2D-F**). We also observed that DENV seroprevalence correlated significantly with factors such as total population, DENV-infested mosquito clusters and domiciliary status of participants (rural/urban) with increased odds (**Figure 2G**). The district-wise population-based seropositivity for SARS-CoV-2 IgG showed a high titre ranging from 78-97% with a mean titre of 167 IU/ml (**Fig 3A**). The number of samples positive for IgG in each district is listed in **S3 Table**.

Figure 2: Correlation between a cluster of DENV-positive mosquito pools with A) DENV-IgM seropositivity, B) DENV-IgG seropositivity, C) Total DENV-seropositivity. Correlation between total anti-DENV IgM positive cases with D) Number of clusters of DENV-infested mosquito pools E) Number of individuals seropositive for DENV, and F) Force of infection of DENV, G) Simple binary regression model assessing the relationship between total population, population density and mosquito clusters positive for DENV with total (IgG and IgM) seropositivity and anti-DENV IgM positive cases.

Figure 3: A) District-wise distribution of anti-SARS-CoV-2 seropositivity in Tamil Nadu. B) Average levels of anti-SARS-CoV-2 IgG titer C) Binary regression model assessing the factors associated with the anti-DENV IgM and IgG seropositivity, D) Linear regression model assessing the factors associated with the level of anti-DENV IgM and IgG.

Of the 5577 samples tested, 88.97% were reactive to SARS-CoV-2 IgG. Other factors including age, sex, vaccination status, type of vaccine administered and anti-SARS-CoV-2 antibodies were strongly associated with dengue seropositivity. While the levels of anti-SARS-CoV-2 correlated significantly with dengue seropositivity, vaccination status correlated similarly with anti-DENV IgM (**Fig 3C**). The association of two different types of SARS-CoV-2 vaccines, viz., BBV152 and AZD1222 with either anti-DENV IgM or IgG positivity did not reveal any significant difference (**Fig 3D**). The comparison of variables like total population, population density and number of DENV-positive mosquito clusters with DENV positivity is presented in **S4a** and **S4b Tables**. The comparison of variables viz., age, gender, vaccination status and type of vaccine administered with DENV seropositivity is presented in **S5a and S5b Tables**.

Discussion

The burden of dengue fever and FOI poses considerable public health challenges to global health. However, the incidence is often underreported as most of the cases remain asymptomatic or misdiagnosed. The WHO data on global burden recorded the highest number of dengue cases (>6 million) and deaths (>7300) in 2023. DENV, being an arbovirus, has an ineludible link between human mobility, anthropogenic, and ecological factors[10]. Climate change and the spatio-temporal distribution of vectors due to *El Niño* cycle, urbanization, population density and human mobility patterns represent key risk factors driving viral transmission and incidence rates[20,21]. In countries like India, despite the implementation of systematic vector surveillance/control programs and access to specific diagnostic tools, increased incidence of dengue fever poses a significant socio-economic burden[22]. An effective and all-inclusive vector and disease control program must therefore include serological, molecular and entomological surveillance for real-time monitoring of DENV circulation.

Both DENV and SARS-CoV-2 are associated with a high risk of severe disease and mortality rate. SARS-CoV-2 evolved into a pandemic in 2020 and thus far recorded >775.52 million cases and 7.05 million deaths until 31 May 2024. After the first vaccine was rolled out in mid-December 2020, 5.5 billion doses have been administered globally. At least 56% of the global population is vaccinated at least with a complete primary series of COVID-19 vaccines and 28% of the population is vaccinated with at least one booster dose (World Health Statistics, WHO; available at www.who.int/data; last accessed on 01 June 2024). Immunization with highly effective and safe vaccines that produced a high titre of nAb reduced the disease burden significantly. However, emerging infections due to the circulating variants of concern with increased transmissibility and severity still pose a serious threat to global health. The vaccine-derived neutralizing antibodies did not offer cross-reactivity against the emerging new variants due to immune evasiveness influencing low transmission[23,24]. Serological cross-reactivity of anti-SARS-CoV-2 with dengue and Zika viruses, especially in DENV-endemic countries has been demonstrated previously[25].

The two viruses, despite having different routes of entry into their host, have similar pathogenesis, overlapping clinical presentations posing diagnostic predicaments and patient management. In addition, the antigenic similarities, heteroserotypic infection, and varying immunogenicity of the four DENV serotypes largely remain ambiguous. Hence, it is necessary to comprehensively analyze both the seroprevalence of DENV and SARS-CoV-2 at the community level to address the conundrum. In our study, the anti-DENV IgM and IgG titres were correlated with SARS-CoV-2 IgG in the community along with the virus screening in mosquitoes during December 2021. This was when both the cases and deaths declined upon vaccination in the timeline of the COVID-19 pandemic. The study was conducted across the state of Tamil Nadu, covering 38 administrative districts that had a population of 72 million.

The co-infection of DENV and SARS-CoV-2 further affects prognosis with increased mortality compared to either infection[26]. Convincing evidence of reduced dengue disease transmission was attributed to public health and social measures during the COVID-19 pandemic[10]. Reports of increased immature stages of Aedes mosquitoes due to COVID-19 lockdowns and subsequently interrupted larval control activities were expected to increase intra-household vector exposure and virus transmission[27]. A few countries reported increased dengue incidence during lockdowns[10,28], but a decline in cases was observed in a vast majority of countries[16].

India is one of the five highly endemic countries for dengue disease despite improved case management with a reduction in case-fatality rate to <0.5%. The Southeast Asian countries have witnessed a 46% upsurge in dengue cases between 2015 and 2019. A recent cross-sectional population-based serosurvey indicated 48.7% seroprevalence in India with the southern part of India which covered five states including Tamil Nadu recording the highest (77%). This indicated a high level of dengue transmission and geographical heterogeneity in the community during the pre-COVID-19 times[29]. A recent study reported a whopping 44.1% decrease in dengue across many dengue endemic regions, beginning March 2020 (2.2 million cases in 2020 versus 4.08 million in 2019)[10]. In Tamil Nadu, a downward trend was observed in dengue-positivity from 8527 cases in 2019 to 2410 in 2020 followed by 6039 cases in 2021 and 6430 in

2022. In 2023, we recorded 4524 cases until September 2023 followed by a sudden spike in dengue cases during the post-monsoon season (October to December) with a total of 10570 cases. This could be attributed to related changes in social activities before and after the pandemic, cross-reactive serological tests with SARS-CoV-2 or increased and improved testing capacity of global laboratories.

Several limitations encountered in previous studies were addressed by including both IgM and IgG assays, testing of large clusters, and proportionate number of mosquito pools in our study design. We showed a district-wise distribution of DENV-positive mosquito pools ranging from 1-7.3% with an average of 3.8%. Seroprevalence of IgM ranged from 0.6-13.3% with an average of 4.12% and IgG prevalence ranged from 1-23.9% with an average of 6.45%. The anti-SARS-CoV-2 IgG prevalence was high ranging from 78.3-97.8%. Interestingly, the anti-SARS-CoV-2 IgG titers correlated with dengue seropositivity indicating possible cross-protection, which however is unclear. Our data on vaccination status correlating with anti-DENV IgM levels needs further substantiation.

The low incidence of dengue during the COVID-19 pandemic due to misdiagnosis or underreporting cannot be ruled out. Hence, all the intense measures to curtail disease transmission should be ascertained. The canonical analysis of virus distribution in mosquitoes together with seroprevalence in the human population should be an integral part of public health measures to curb mosquito populations and pathogen transmission. Further, in addition to the inclusion of both IgM and IgG seroprevalence, molecular typing could add details to the circulating dengue serotype and disease severity in the population.

The current study indicated the potential role of high titres of pre-existing anti-SARS-CoV-2 against DENV. However, the study suffered certain limitations that include the inability to demonstrate (1) a correlation of low titer of anti-SARS-CoV-2 with high anti-DENV seroprevalence in the population to further convince our findings; (2) cross-reactivity of the two viruses and viral interference by the immune cells in human cell lines; (3) deviations in patient's clinical outcome; (4) DENV serotyping of the circulating viruses; (5) association of human mobility, public health, and social constraints. The inclusion of these factors will prove any association between the DENV infection and SARS-CoV-2 infection and if was a one-time phenomenon or observed at every emergence of SARS-CoV-2 variants across the globe.

Conclusion

Dengue fever and SARS-CoV-2 continue to remain major global public health concerns, predominantly in the tropical world where dengue case incidence is exponentially increasing annually, and there is an ongoing geographical expansion of transmission areas and cocirculation of multiple DENV serotypes. It is of paramount importance to establish laboratory-based sentinel surveillance with coordinated entomological and molecular surveillance for early diagnosis, prevention, and control of arboviral infections.

Author Contributions

STS, AS, SP, PK, RA, ABKC, SS, YKY, AM, ML, PB, SNB, VV, APD, EMS and SR designed the study and were responsible for conceptualization and data curation. STS, AARA, SC, YKY, PA, RPP, SS, AK, NG, MK, ML, VV, PB, APD, EMS and SR conducted the analysis and were responsible for methodology, formal analysis, validation, and visualization. STS, YKY, SS, ML, VV, EMS and SR wrote the first draft of the manuscript. All authors provided critical inputs and approved the final version of the manuscript for publication. All authors fulfil the criteria for authorship as per the ICMJE recommendations.

References

1. Ferreira-de-Lima VH, Lima-Camara TN. Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: a systematic review. Parasit Vectors. 2018;11: 77. doi:10.1186/s13071-018-2643-9

2. Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC. Dengue. Lancet. 2024;403: 667–682. doi:10.1016/S0140-6736(23)02576-X

3. Leta S, Beyene TJ, De Clercq EM, Amenu K, Kraemer MUG, Revie CW. Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus. International Journal of Infectious Diseases. 2018;67: 25–35. doi:10.1016/j.ijid.2017.11.026

4. Urmi TJ, Mosharrafa R Al, Hossain MdJ, Rahman MS, Kadir MF, Islam MdR. Frequent outbreaks of dengue fever in South Asian countries—A correspondence analyzing causative factors and ways to avert. Health Sci Rep. 2023;6. doi:10.1002/hsr2.1598

5. Bodinayake CK, Tillekeratne LG, Nagahawatte A, Devasiri V, Kodikara Arachchi W, Strouse JJ, et al. Evaluation of the WHO 2009 classification for diagnosis of acute dengue in a large cohort of adults and children in Sri Lanka during a dengue-1 epidemic. PLoS Negl Trop Dis. 2018;12. doi:10.1371/JOURNAL.PNTD.0006258

6. Yong YK, Wong WF, Vignesh R, Chattopadhyay I, Velu V, Tan HY, et al. Dengue Infection - Recent Advances in Disease Pathogenesis in the Era of COVID-19. Front Immunol. 2022;13. doi:10.3389/FIMMU.2022.889196

7. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016;2. doi:10.1038/NRDP.2016.55

8. Tangsathapornpong A, Thisyakorn U. Dengue amid COVID-19 pandemic. PLOS Global Public Health. 2023;3: e0001558. doi:10.1371/JOURNAL.PGPH.0001558

9. Ahmad Zaki R, Xin NZ. Dengue Trend During COVID-19 Pandemic in Malaysia. Asia Pac J Public Health. 2023;35: 62–64. doi:10.1177/10105395221134655

10. Chen Y, Li N, Lourenço J, Wang L, Cazelles B, Dong L, et al. Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study. Lancet Infect Dis. 2022;22: 657. doi:10.1016/S1473-3099(22)00025-1

494 11. Trunfio M, Savoldi A, Viganò O, d'Arminio Monforte A. Bacterial coinfections in dengue virus
495 disease: what we know and what is still obscure about an emerging concern. Infection. 2017;45.
496 doi:10.1007/S15010-016-0927-6

497 12. Gebremariam TT, Schalling HDFH, Kurmane ZM, Danquah JB. Increasing prevalence of malaria
498 and acute dengue virus coinfection in Africa: a meta-analysis and meta-regression of cross-
499 sectional studies. Malar J. 2023;22: 1–11. doi:10.1186/S12936-023-04723-Y/FIGURES/7

500 13. Irekeola AA, Engku Nur Syafirah EAR, Islam MA, Shueb RH. Global prevalence of dengue and
501 chikungunya coinfection: A systematic review and meta-analysis of 43,341 participants. Acta
502 Trop. 2022;231: 106408. doi:10.1016/j.actatropica.2022.106408

503 14. Sasmono RT, Santoso MS. Movement dynamics: reduced dengue cases during the COVID-19
504 pandemic. Lancet Infect Dis. 2022;22: 570–571. doi:10.1016/S1473-3099(22)00062-7

505 15. Tang KHD. Movement control as an effective measure against Covid-19 spread in Malaysia: an
506 overview. Z Gesundh Wiss. 2022;30: 583–586. doi:10.1007/S10389-020-01316-W

507 16. Sharma H, Ilyas A, Chowdhury A, Poddar NK, Chaudhary AA, Shilbayeh SAR, et al. Does COVID-19
508 lockdowns have impacted on global dengue burden? A special focus to India. BMC Public Health.
509 2022;22. doi:10.1186/S12889-022-13720-W

510 17. Khan S, Akbar SMF, Nishizono A. Co-existence of a pandemic (SARS-CoV-2) and an epidemic
511 (Dengue virus) at some focal points in Southeast Asia: Pathogenic importance, preparedness, and
512 strategy of tackling. The Lancet Regional Health - Southeast Asia. 2022;4: 100046.
513 doi:10.1016/j.lansea.2022.100046

514 18. Vojdani A, Vojdani E, Melgar AL, Redd J. Reaction of SARS-CoV-2 antibodies with other
515 pathogens, vaccines, and food antigens. Front Immunol. 2022;13.
516 doi:10.3389/FIMMU.2022.1003094

517 19. Cheng YL, Chao CH, Lai YC, Hsieh KH, Wang JR, Wan SW, et al. Antibodies against the SARS-CoV-2
518 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis. Front Immunol. 2022;13.
519 doi:10.3389/FIMMU.2022.941923

520 20. Stoddard ST, Forshey BM, Morrison AC, Paz-Soldan VA, Vazquez-Prokopec GM, Astete H, et al.
521 House-to-house human movement drives dengue virus transmission. Proceedings of the National
522 Academy of Sciences. 2013;110: 994–999. doi:10.1073/pnas.1213349110

523 21. Tsheten T, Gray DJ, Clements ACA, Wangdi K. Epidemiology and challenges of dengue
524 surveillance in the WHO South-East Asia Region. Trans R Soc Trop Med Hyg. 2021;115: 583–599.
525 doi:10.1093/TRSTMH/TRAA158

526 22. Pilot E, Nittas V, Murthy GVS. The Organization, Implementation, and Functioning of Dengue
527 Surveillance in India—A Systematic Scoping Review. Int J Environ Res Public Health. 2019;16.
528 doi:10.3390/IJERPH16040661

529 23. Nguyen TTN, Choo EM, Nakamura Y, Suzuki R, Shiina T, Shin-I T, et al. Pre-existing cross-reactive
530 neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19
531 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants,
532 Vietnam. International Journal of Infectious Diseases. 2024;139: 109–117.
533 doi:10.1016/j.ijid.2023.11.008

534 24. Selvavinayagam ST, Karishma SJ, Hemashree K, Yong YK, Suvaithenamudhan S, Rajeshkumar M,
535 et al. Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India
536 - a cohort study. The Lancet regional health Southeast Asia. 2023;19.
537 doi:10.1016/J.LANSEA.2023.100272

538 25. Munoz-Jordan J, Cardona J, Beltrán M, Colón C, Schiffer J, Stewart-Clark E, et al. Evaluation Of
539 Serologic Cross-Reactivity Between Dengue Virus And Sars-Cov-2 In Patients With Acute Febrile
540 Illness — United States And Puerto Rico, April 2020–March 2021. MMWR Recommendations and
541 Reports. 2022;71: 375–377. doi:10.15585/mmwr.mm7110a3

542 26. Agudelo-Rojas OL, Rebellón-Sànchez DE, Torres JL, Zapata-Vásquez IL, Rodríguez S, Robles-
543 Castillo S, et al. Co-Infection between Dengue Virus and SARS-CoV-2 in Cali, Colombia. Am J Trop
544 Med Hyg. 2023;109: 536–541. doi:10.4269/AJTMH.22-0717

545 27. Daniel Reegan A, Rajiv Gandhi M, Cruz Asharaja A, Devi C, Shanthakumar SP. COVID-19 lockdown:
546 impact assessment on Aedes larval indices, breeding habitats, effects on vector control
547 programme and prevention of dengue outbreaks. Heliyon. 2020;6: e05181.
548 doi:10.1016/J.HELIYON.2020.E05181

549 28. Ong SQ, Ahmad H, Ngesom AMM. Implications of the COVID-19 Lockdown on Dengue
550 Transmission in Malaysia. Infect Dis Rep. 2021;13: 148. doi:10.3390/IDR13010016

551 29. Murhekar M V., Kamaraj P, Kumar MS, Khan SA, Allam RR, Barde P, et al. Burden of dengue
552 infection in India, 2017: a cross-sectional population based serosurvey. Lancet Glob Health.
553 2019;7: e1065–e1073. doi:10.1016/S2214-109X(19)30250-5

554
555

Supporting information

S1 Table: District-wise DENV positive rate in mosquito pools for the year 2023
S2 Table: District-wise distribution of DENV seropositivity
S3 Table: District-wise distribution of SARS-CoV-2 seropositivity
S4a Table: Mosquito pools positive for DENV and DENV seropositivity
S4b Table: Mosquito positive for DENV and DENV positive case
S5a Table: Factors associated with DENV seropositivity
S5b Table: Factors associated with DENV IgM and IgG level


A.
Tamil Nadu
Thiruvallur
Chennai
Vellore
Ranipet
Kancheepuram
Krishnagiri
Tiruppathur
Chengalpattu
Tiruvannamalai
Dharmapuri
Villupuram
Kallakurichi
Salem
Erode
Nilgiris
Cuddalore
Namakkal
Perambalur
Ariyalur
Mayiladuthurai
Tiruppur
Tiruchirappalli
Coimbatore
Karur
Thanjavur
Thiruvarur
Dindigul
Pudukkottai
Nagapattinam
Madurai
Theni
Sivagangga
Ramanathapuram
Virudhunagar
Tenkasi
Thoothukudi
Tirunelveli
Kanyakumari
Percentage of mosquito positive for DENV
0
2%
4%
8%
12%
B.
Mosquito pools tested by year
Mosquito pool tested
Mosquito pool tested positive
15000
13000
11000
9000
7000
5000
3000
1000
2016
2017
2018
2019
2020
2021
2022
2023
C.
Seroprevalence of DENV
1%
5%
7.5%
10%
15%
20%
25%
D.
Anti-DENV
IgM
IgG
206
23
333
Total = 562
E.
Incidence
70
60
50
40
30
20
10
0
IgM seropositivity
IgG seropositivity
Total seropositivity
Ariyalur
Chengalpattu
Chennai
Coimbatore
Cuddalore
Dharmapuri
Dindigul
Erode
Kallakurichi
Kanchipuram
Kanyakumari
Karur
Krishnagiri
Madurai
Mayiladuthurai
Nagapattinam
Namakkal
Perambalur
Pudukkottai
Ramanathapuram
Ranipet
Salem
Sivagangga
Tenkasi
Thanjavur
The Nilgiris
Theni
Thiruppur
Thiruvallur
Thiruvarur
Thiruvannamalai
Tiruchirappalli
Tirunelveli
Tuticorin
Vellore
Villupuram
Virudhunagar
F.
Number
1200
1000
800
600
400
200
0
% DENV seropositivity
12
10
8
6
4
2
0
10-19
20-29
30-39
40-49
50-59
60-69
70-79
> 80
Total
DENV seropositivity
% DENV seropositivity
G.
IgM titer, mean (95% CI)
IgG titer, mean (95% CI)
IgM titer
IgG titer
30
25
20
15
10
5
40
35
30
25
20
15
10-19
20-29
30-39
40-49
50-59
60-69
70-79
> 80
H.
Force of infection
<0.5
<1
1
2
3
4
>4
no./1000 person/year


A.
IgM seropositivity
R = 0·305
P = 0·047 *
B.
IgG seropositivity
R = 0·308
P = 0·152
C.
Total seropositivity
R = 0·579
P = 0·0407 *
No. mosquito positive for DENV
D.
No. of mosquito cluster +ve for DENV
R = 0·181
P = 0·245
E.
No. of people seropositive for for DENV
R = 0·136
P = 0·085 †
F.
FOI of DENV
R = 0·02
P = 0·87
Total DENV case
† having a trend of significant
G.
Total DENV seropositivity
Total DENV case
Variables
Odds ratio
Coef. (95% CI)
P-value
Total population
43·1 (31·1 – 55·2) <0·001***
334·2 (51·7 – 616·7) 0·022 *
Rural population
28·9 (13·3 – 44·6) <0·001***
50 (-321·1 – 421·2) 0·787
Urban population
18·3 (11·6 – 25·1) <0·001***
210·1 (775 – 342·6) 0·003 **
Population density (10 units)
0·11 (0·07 – 0·02) <0·001***
0·092 (0·002 – 0·18) 0·042 *
Mosquito clusters +ve for DENV
No.
0·27 (-0·11 – 0·65) 0·158
3·8 (-2·55 – 10·14) 0·234
%
2·53 (0·47 – 4·59) 0·018 *
23·34 (12·6 – 59·3) 0·019 *
DENV seropositivity
8·43 (3·92 – 12·95) <0·001***
increased odds


A.
Thiruvallur
Chennai
Vellore
Ranipet
Kancheepuram
Krishnagiri
Tirupathur
Tiruvannamalai
Chengalpattu
Villupuram
Dharmapuri
Kallakuruchi
Salem
Nilgiris
Erode
Cuddalore
Namakkal
Perambalur
Ariyalur
Mayiladuthurai
Thiruppur
Thiruchirapalli
Karur
Coimbatore
Thiruvarur
Nagapattinam
Thanjavur
Dindigul
Pudukottai
Theni
Madurai
Sivaganga
Virudhunagar
Ramanathapuram
Tenkasi
Thoothukudi
Tirunelveli
Kanyakumari
Seroprevalence of SARS-COV-2
75% 80% 85% 90% 95% >95%
B.
Sivaganga
Madurai
Thiruvarur
Thiruchirapalli
Tirunelveli
Theni
Ramanathapuram
Cuddalore
Nagapattinam
Vellore
Tiruvannamalai
Tiruppur
Tirupathur
Ranipet
Dharmapuri
Thoothukudi
Salem
Perambalur
Kanyakumari
Nilgiris
Thiruvallur
Coimbatore
Namakkal
Tenkasi
Virudhunagar
Krishnagiri
Thanjavur
Pudukottai
Chengalpattu
Villupuram
Dindigul
Kancheepuram
Erode
Mayiladudhurai
Chennai
Ariyalur
Karur
Kallakuruchi
0 50 100 150 200 250
Anti SARS-CoV-2 IgG titer
C. Factors associated with dengue seropositivity
Binary regression
Variables Coefficients (95% CI) P-value Coefficients (95% CI) P-value
Age 1 (0·99 – 1·08) 0·963 1 (0·99 – 1·01) 0·983
Gender 0·83 (0·65 – 1·06) 0·137 1·19 (0·98 – 1·44) 0·081
Vaccination 1·29 (0·9 – 1·85) 0·167 1·19 (0·9 – 1·56) 0·221
AZD1222 0·99 (0·63 – 1·58) 0·987 1·23 (0·88 – 1·73) 0·231
BBV152 0·98 (0·61 – 1·57) 0·931 0·81 (0·58 – 1·14) 0·233
Anti-SARS-CoV-2 IgG positive 0·811 (0·63 – 0·94) 0·044 * 0·88 (0·73 – 1·06) 0·192
0.0 0.5 1.0 1.5 2.0
D. Factors associated with plasma anti-DENV antibodies
Linear regression
Variables Coefficients (95% CI) P-value Coefficients (95% CI) P-value
Age -0·005 (-0·024 – 0·014) 0·599 -0·004 (-0·02 – 0·012) 0·651
Gender -0·55 (-1·16 – 0·072) 0·084 -0·05 (-0·55 – 0·45) 0·832
Vaccination -1·23 (-2·16 – -0·3) 0·01 ** 0·44 (-0·31 – 1·19) 0·247
AZD1222 0·11 (-0·39 – 0·6) 0·667 -0·23 (-1·21 – 0·76) 0·652
BBV152 -0·19 (-0·69 – 0·31) 0·458 0·19 (-0·8 – 1·19) 0·703
Anti-SARS-CoV-2 IgG (100 units) -0·5 (-1·03 – -0·03) 0·037 * 0·4 (-0·03 – 0·83) 0·068
-3 -2 -1 0 1
-2 -1 0 1 2
anti-DENV IgM
anti-DENV IgG
significant association
non-significant association